Home/Filings/4/0001209191-04-020327
4//SEC Filing

GIMV NV 4

Accession 0001209191-04-020327

CIK 0001062216other

Filed

Apr 11, 8:00 PM ET

Accepted

Apr 12, 4:54 PM ET

Size

18.9 KB

Accession

0001209191-04-020327

Insider Transaction Report

Form 4
Period: 2004-04-08
GIMV NV
Other
Transactions
  • Conversion

    Common Stock

    2004-04-08+166,408166,408 total
  • Conversion

    Series C Convertible Preferred Stock

    2004-04-08200,0000 total
    Common Stock (71,170 underlying)
  • Conversion

    Series D Convertible Preferred Stock

    2004-04-081,395,3490 total(indirect: See Footnote)
    Common Stock (465,116 underlying)
  • Conversion

    Series B Convertible Preferred Stock

    2004-04-08285,7140 total
    Common Stock (95,238 underlying)
  • Conversion

    Common Stock

    2004-04-08+465,116465,116 total(indirect: See Footnote)
Transactions
  • Conversion

    Series B Convertible Preferred Stock

    2004-04-08285,7140 total
    Common Stock (95,238 underlying)
  • Conversion

    Common Stock

    2004-04-08+465,116465,116 total(indirect: See Footnote)
  • Conversion

    Series D Convertible Preferred Stock

    2004-04-081,395,3490 total(indirect: See Footnote)
    Common Stock (465,116 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2004-04-08200,0000 total
    Common Stock (71,170 underlying)
  • Conversion

    Common Stock

    2004-04-08+166,408166,408 total
Footnotes (5)
  • [F1]The shares of Series D Convertible Preferred Stock reported consist of shares held of record by each of the entities listed below. GIMV and Adviesbeheer GIMV Life Sciences each owned 1,186,047 and 209,302 shares of Series D Convertible Preferred Stock respectively. Upon conversion, GIMV and Adviesbeheer GIMV Life Sciences each own 395,349 and 69,767 shares of common stock respectively. Each of the Filing Persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
  • [F2]Each share of Convertible Preferred Stock converted into .3333 shares of Common Stock.
  • [F3]These securities automatically converted into Common Stock upon the closing of the Issuer's intitial public offering.
  • [F4]These securities do not have an expiration date.
  • [F5]Each share of Convertible Preferred Stock converted into .3559 shares of Common Stock.

Issuer

MEMORY PHARMACEUTICALS CORP

CIK 0001062216

Entity typeother

Related Parties

1
  • filerCIK 0001284391

Filing Metadata

Form type
4
Filed
Apr 11, 8:00 PM ET
Accepted
Apr 12, 4:54 PM ET
Size
18.9 KB